Massachusetts 2023-2024 Regular Session

Massachusetts Senate Bill S1435 Compare Versions

Only one version of the bill is available at this time.

Old	New	Differences
1	1	1 of 1
2	2	SENATE DOCKET, NO. 1753 FILED ON: 1/19/2023
3	3	SENATE . . . . . . . . . . . . . . No. 1435
4	4	The Commonwealth of Massachusetts
5	5	_________________
6	6	PRESENTED BY:
7	7	Susan L. Moran
8	8	_________________
9	9	To the Honorable Senate and House of Representatives of the Commonwealth of Massachusetts in General
10	10	Court assembled:
11	11	The undersigned legislators and/or citizens respectfully petition for the adoption of the accompanying bill:
12	12	An Act authorizing pharmacists to provide opioid use disorder treatment.
13	13	_______________
14	14	PETITION OF:
15	15	NAME:DISTRICT/ADDRESS :Susan L. MoranPlymouth and BarnstableJoanne M. ComerfordHampshire, Franklin and Worcester2/6/2023 1 of 2
16	16	SENATE DOCKET, NO. 1753 FILED ON: 1/19/2023
17	17	SENATE . . . . . . . . . . . . . . No. 1435
18	18	By Ms. Moran, a petition (accompanied by bill, Senate, No. 1435) of Susan L. Moran and Joanne
19	19	M. Comerford for legislation to authorize pharmacists to provide opioid use disorder treatment.
20	20	Public Health.
21	21	The Commonwealth of Massachusetts
22	22	_______________
23	23	In the One Hundred and Ninety-Third General Court
24	24	(2023-2024)
25	25	_______________
26	26	An Act authorizing pharmacists to provide opioid use disorder treatment.
27	27	Be it enacted by the Senate and House of Representatives in General Court assembled, and by the authority
28	28	of the same, as follows:
29	29	1 Section 24B ½ of chapter 112 of the General Laws, as appearing in the 2020 Official
30	30	2Edition, is hereby amended by striking out subsection (c) and inserting thereof the following:-
31	31	3 (c) Collaborative drug therapy management shall only be allowed in the following
32	32	4settings: (1) hospitals licensed pursuant to section 51 of chapter 111, subject to approval by the
33	33	5medical staff executive committee at a licensed hospital or designee; (2) long-term care facilities
34	34	6licensed pursuant to section 71 of chapter 111, subject to approval by the long-term care
35	35	7facilities' medical director or designee; (3) inpatient or outpatient hospice settings licensed
36	36	8pursuant to section 57D of chapter 111, subject to approval by the hospice's medical director or
37	37	9designee; (4) ambulatory care clinics licensed pursuant to section 51 of chapter 111, with on-site
38	38	10supervision by the attending physician and a collaborating pharmacist, subject to approval by the
39	39	11ambulatory care clinic's medical staff executive committee or designee, or medical director or
40	40	12designee; (5) collaborating pharmacists in a retail drug business, as registered in section 38 of 2 of 2
41	41	13chapter 112 and limited by this section, with supervision by physicians according to the terms of
42	42	14their collaborative practice agreements and limited to the following: patients 18 years of age or
43	43	15older; an extension by 30 days of current drug therapy prescribed by the supervising physician;
44	44	16and administration of vaccines or initiation of medications pursuant to a diagnosis,
45	45	17discontinuation, and/or modification of dosages of medications prescribed by the supervising
46	46	18physicians for substance use disorders, asthma, chronic obstructive pulmonary disease, diabetes,
47	47	19hypertension, hyperlipidemia, congestive heart failure, HIV or AIDS, osteoporosis and co-
48	48	20morbidities identified by the supervising physician for the individual patient along with the
49	49	21primary diagnosis. The collaborative practice agreement shall specifically reference each disease
50	50	22state being co-managed. A patient shall be referred by supervising physicians to that physicians’
51	51	23collaborating pharmacists and shall be given notice of the collaboration and shall consent to the
52	52	24collaboration. Pharmacists in the retail setting, who have a collaborative practice agreement with
53	53	25supervising physicians which specifically allows initial prescriptions for referred patients of the
54	54	26supervising physician, may issue prescriptions for schedule II-VI controlled substances, as
55	55	27defined in clause 6 of section 3 of chapter 94C. Collaborative Practice Agreements with
56	56	28pharmacists in a retail setting that include controlled substances shall only be used to treat
57	57	29substance use disorders as defined by section 35 of chapter 123 or any disorder described in the
58	58	30most recent edition of the Diagnostic and Statistical Manual of Mental Disorders. Such
59	59	31prescriptions shall be for a patient diagnosis specified in the supervising physician's individual
60	60	32referral of that patient. A copy of the prescription shall be sent to the supervising physician
61	61	33within 24 hours.